PharmaCyte Biotech, Inc. (PMCB): R&D Expense
$391.3K
Year ended 2026-04-30
$356.1K
Trailing 12 months to 2026-07-31
-5.8%
3-year compound annual growth
-15.6%
5-year compound annual growth
-12.0%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | $391.3K | -10.7% | 2026-07-29, From 2025-05-01 |
| 2025-04-30 | $438.4K | +7.6% | 2026-07-29, From 2024-05-01 |
| 2024-04-30 | $407.4K | -13.0% | 2025-08-11, From 2023-05-01 |
| 2023-04-30 | $468.5K | -32.2% | 2024-08-13, From 2022-05-01 |
| 2022-04-30 | $690.9K | -24.6% | 2023-07-31, From 2021-05-01 |
| 2021-04-30 | $916.2K | +204.2% | 2022-07-28, From 2020-05-01 |
| 2020-04-30 | $301.2K | -34.5% | 2021-08-10, From 2019-05-01 |
| 2019-04-30 | $460.1K | -77.0% | 2020-08-13, From 2018-05-01 |
| 2018-04-30 | $2.00M | +69.0% | 2019-08-13, From 2017-05-01 |
| 2017-04-30 | $1.18M | -16.0% | 2018-07-20, From 2016-05-01 |
| 2016-04-30 | $1.41M | -59.5% | 2017-07-27, From 2015-05-01 |
| 2015-04-30 | $3.48M | +974.8% | 2016-07-29, From 2014-05-01 |
| 2014-04-30 | $323.5K | n/a | 2016-07-29, From 2013-05-01 |
| 2013-04-30 | $0 | n/a | 2016-01-19, From 2012-05-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $391.3K | -10.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Amgen Inc (AMGN) | 2025-12-31 | $7.27B | +21.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $54.18M | +25.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $9.08M | +33.1% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $1.78B | -10.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $5.80B | -1.8% |
Compare PMCB, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗